Breast cancer metastatic+1
Not recruitingStudy of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab
Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab
- Disease:Breast cancer metastaticHER2 positive breast cancer
- Substances:Alpelisib
Spain- Participants:18–64 years · 65+ years
- Substances:Alpelisib
- Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama










